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L E T T E R  T O  T H E  E D I T O R
Haploinsufficiency of KMT2D is sufficient to cause Kabuki 
syndrome and is compatible with life
Dear Editor,
Kabuki syndrome (KS), also known as Niikawa-Kuroki syn-
drome, is a Mendelian disorder of the epigenetic machinery 
which occurs in approximately 1:32,000 births characterized 
by intellectual disability, facial and limb dysmorphic fea-
tures, and postnatal growth retardation. Pathogenic variants 
in genes KMT2D and KDM6A are found in 70% of patients 
with KS (type 1 MIM#:147920 and type 2 MIM#:300867 
respectively). KMT2D and KDM6A are both highly con-
strained genes (pLI  =  1.0) suggesting that both genes are 
intolerant to heterozygous loss-of-function variation and 
thus haploinsufficient. While true haploinsuffiency through 
deletion of the entire locus of KDM6A is a well-established 
cause of KS2 (Lederer et al., 2012), no patient has yet to be 
described with a germline deletion of the entire KMT2D gene 
and it has been hypothesized that constitutional deletions of 
KMT2D may be embryonic lethal in humans (Banka et al., 
2013). Despite this, KMT2D is classified in ClinGen as hav-
ing sufficient evidence for haploinsufficiency based on the 
large number of truncating mutations that are causative of KS 
(dbVar: nsv997197/nssv3442621). Most molecularly con-
firmed cases of KS are from heterozygous pathogenic vari-
ants in KMT2D (94% n = 621/660) but in published reports 
only six cases (~0.9% n = 6/621) involve any type of KMT2D 
deletion larger than 20 basepairs (Bögershausen et al., 2016). 
Five of these involve small intragenic deletions and the sixth 
case is a mosaic whole gene deletion in a patient (Banka et 
al., 2013; Bögershausen et al., 2016). While it is assumed that 
mutations in KMT2D are mainly loss of function mutations, it 
has not been clear whether this gene is truly dosage sensitive.
Here, we describe the first published patient with a consti-
tutional deletion of KMT2D with classical KS. Our patient is 
the first child of healthy parents born at term with a 2-vessel 
cord and intrauterine growth restriction. She required inter-
vention for hypothermia and feeding intolerance and was sub-
sequently admitted to the pediatric intensive care unit (PICU) 
for hyperinsulinemic hypoglycemia. At 10  months of age, 
she is G-tube fed with persistent hyperinsulinemic hypogly-
cemia requiring diazoxide and continuous overnight feeds, a 
phenotype seen in other children with KS1. She is hypotonic 
(trunk > extremities), with left hip dysplasia, joint laxity, and 
premature thelarche, all features previously seen in KS1. She 
has moderate bilateral hearing loss without a history of ear in-
fections. An echocardiogram revealed a small-medium atrial 
septal defect and a renal ultrasound was normal. She has the 
characteristic KS facial gestalt including elongated palpebral 
fissures, long eyelashes, arched eyebrows with sparseness of 
the lateral third of the brow, ptosis, a broad nasal root, flat 
nasal tip, high arched palate, micrognathia, and large cup-
shaped ears with an abnormally-formed right ear pinna with 
pits (Figure 1a). The patient's mother also reports nocturnal 
lagophthalmos, a feature frequently  reported in KS1. Our 
patient exhibits other distinctive physical features that are 
common among individuals with KS, including persistence 
of the fetal fat pads, and short 5th fingers with clinodactyly 
bilaterally (Figure 1a). She also has mild 2-3 toe syndactyly, 
hypoplastic nails of hands and feet, and fused labia. As is 
seen in many children with KS, our patient demonstrates 
developmental delay. At 10 months she is cooing and smil-
ing but not babbling, sits unassisted and has begun to pull 
to stand. Recently a phenotypic score has been validated for 
which the median score for molecularly confirmed KS is 6/10 
(Makrythanasis et al., 2013). Our patient scores 5 on this sys-
tem indicating that she objectively has a phenotype that fits 
KS very well (Figure 1b).
Microarray analysis revealed a 434.6  kb deletion of 
12q13.1 (Figure 1c). This deletion on chromosome 12 
from 49,034,325 to 49,468,966 (hg19, ClinVar  accession 
SCV000920777) encompasses 23 genes, five of which are 
genes associated with disease in OMIM (ADCY6, CCDC65, 
WNT10B, WNT1, KMT2D). Of these, only three diseases are 
inherited in an autosomal dominant pattern, Selective Tooth 
Agenesis-8 (WNT10B MIM#:617073), susceptibility to early 
onset osteoporosis (WNT1 MIM#:615221) and KS (KMT2D 
MIM#:602113). At 10  months, our patient has seemingly 
normal dentition with eruption of three normally formed 
teeth, and there have been no issues suggesting abnormal 
bone density. Our patient is the first known case to date of 
a nonmosaic whole-gene deletion of KMT2D and presents 
with the typical clinical phenotype of KS. Early lethality 
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due to haploinsufficency of KMT2D may be supported by 
the fact that on our evaluation of DECIPHER deletions and 
duplications that include all of KMT2D, there is marked 
overrepresentation of duplications (11/12), with the only de-
letion being very large (101.3 Mb). Though we cannot rule 
out reduced viability of pregnancies with a KMT2D deletion, 
deletion of KMT2D does not appear to be embryonic lethal as 
our patient is alive and well. Additionally, one would expect 
our patient to have a more severe clinical presentation than 
the average individual with KS if heterozygous deletion of 
KMT2D were to cause embryonic or in utero lethality; how-
ever, our patient's clinical presentation is no more severe than 
F I G U R E  1  Phenotype of our patient with KMT2D haploinsufficiency. (a) Photos taken at 10 months show typical facial features and hand 
abnormalities such as persistent fetal fat pads (black arrows). (b) Our patient has a phenotype score of 5/10. (c) The 432 kb region which is deleted 
in our patient (black). Vertical green bar shows location of KMT2D. Genes highlighted in cyan are associated with an OMIM disease phenotype
Kabuki Syndrome Features Paent 
Features
Kabuki 
Score
Facial features
(1-5 points)
0-3 features = 1 point
4-6 features = 2 points
7-9 features = 3 points
10-12 features = 4 
points
13-15 features = 5 
points
Arched eyebrows with 
sparse lateral third
x
3
Long palpebral fissures x
Everted lower eyelids -
Ptosis x
Strabismus -
Blue sclerae -
Large dysplasc ears x
Broad nasal root x
Flat nasal p x
Abnormal denon -
Oligodona -
High or cle palate x
Micrognathia x
Thin vermillion of the 
upper lip and full lower 
lip
x
Lip nodules -
Limb and extremity 
features
(0-1 point)
0-1 features = 0 points
2-4 features = 1 point
Brachydactyly or 
clinodactyly
x
1Hip dislocaon x
Lax joints x
Persistent fetal pads x
Microcephaly (1 point) - 0
Short stature (1 point) - 0
Heart (1 point) x 1
Kidney (1 point) - 0
TOTAL (0-10 points) 5
(a) (b)
(c)
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the average Kabuki patient, and from a congenital anomaly 
standpoint, her malformations are on the milder end of the 
spectrum.
Our patient is therefore the first described case of con-
stitutional whole-gene deletion of KMT2D in a patient with 
classical features of KS. The relatively small size of the de-
letion identified leads us to conclude that the loss of KMT2D 
is the principal cause of her clinical phenotype. This supports 
the notion that a primary cause of KS is decreased amounts 
of KMT2D protein rather than altered function which can be 
seen with gain-of-function or dominant-negative mutations.
ACKNOWLEDGMENTS
We are grateful to the patient's family for participating in 
this study. Patient was consented on our Epigenetics and 
Chromatin Clinic Consent according to institutional guide-
lines with IRB approval. HTB is funded by the Icelandic 
Research Fund (195835-051) and a grant from the Louma 
G. Foundation. This study makes use of data generated by 
the DECIPHER community. A full list of centers who con-
tributed to the generation of the data is available from http://
decip her.sanger.ac.uk and via email from decipher@sanger.
ac.uk. Funding for the project was provided by the Wellcome 
Trust.
CONFLICT OF INTEREST
HTB is a consultant for Millennium Pharmaceuticals.
CONFLICT OF INTEREST
HTB is a consultant for Millennium Pharmaceuticals.
DATA AVAILABILITY STATEMENT
The variant presented in this manuscript has been submitted 
to ClinVar (accession SCV000920777).
Teresa Romeo Luperchio1
Carolyn D. Applegate1
Olaf Bodamer2,3
Hans Tomas Bjornsson1,4,5,6
1McKusick-Nathans Department of Genetic Medicine, 
Johns Hopkins University School of Medicine, 
Baltimore, MD, USA
2Division of Genetics and Genomics, Department 
of Pediatrics, Boston Children's Hospital, Harvard 
Medical School, Boston, MA, USA
3Broad Institute of MIT and Harvard University, 
Cambridge, MA, USA
4Department of Pediatrics, Johns Hopkins University 
School of Medicine, Baltimore, MD, USA
5Faculty of Medicine, School of Health Sciences, 
University of Iceland, Reykjavik, Iceland
6Landspitali University Hospital, Reykjavik, Iceland
Correspondence
Hans Tomas Bjornsson, McKusick-Nathans Department 
of Genetic Medicine, Johns Hopkins University School of 
Medicine, Baltimore, MD 21205, USA.
Email: hbjorns1@jhmi.edu
ORCID
Teresa Romeo Luperchio   https://orcid.
org/0000-0001-8586-3101 
Olaf Bodamer   https://orcid.org/0000-0002-7847-552X 
Hans Tomas Bjornsson   https://orcid.
org/0000-0001-6635-6753 
REFERENCES
Banka, S., Howard, E., Bunstone, S., Chandler, K. E., Kerr, B., 
Lachlan, K., … Donnai, D. (2013). MLL2 mosaic mutations 
and intragenic deletion-duplications in patients with Kabuki 
syndrome. Clinical Genetics, 83(5), 467–471. https ://doi.
org/10.1111/j.1399-0004.2012.01955.x
Bögershausen, N., Gatinois, V., Riehmer, V. Kayserili, H., Becker, J., 
Thoenes, M., … Wollnik, B. (2016). Mutation update for kabuki 
syndrome genes KMT2D and KDM6A and further delineation of 
X-linked kabuki syndrome subtype 2. Human Mutation, 37(9), 847–
864. https ://doi.org/10.1002/humu.23026 
Lederer, D., Grisart, B., Digilio, M. C., Benoit, V., Crespin, M., Ghariani, 
S. C., … Verellen-Dumoulin, C. (2012). Deletion of KDM6A, a 
histone demethylase interacting with MLL2, in three patients with 
Kabuki syndrome. American Journal of Human Genetics, 90(1), 
119–124. https ://doi.org/10.1016/j.ajhg.2011.11.021
Makrythanasis, P., van Bon, B. W., Steehouwer, M., Rodríguez-
Santiago, B., Simpson, M., Dias, P., … Hoischen, A. (2013). MLL2 
mutation detection in 86 patients with Kabuki syndrome: A gen-
otype-phenotype study. Clinical Genetics, 84(6), 539–545. https ://
doi.org/10.1111/cge.12081 
